(Journal Article): Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes.
 
Ahren B, Gomis R, Standl E, Mills D, Schweizer A
 
IN: Diabetes Care 2004; 27(12):2874-2880
Impact Factor(s) of Diabetes Care: 7.071 (2004), 7.501 (2003), 5.477 (2002), 5.404 (2001)

ABSTRACT: OBJECTIVE: To assess the 12- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 versus placebo in patients with type 2 diabetes continuing metformin treatment. RE... Click HERE for details